Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Publications
2013
2012 Annual Report
2012 Financial Statements
2012
Follow-up on CEWG Report on Research and Development Financing and Coordination 2012
ACTA is dead, long live ACTA? ACTA-like measures still in EU IP policies
Time for the final push: Say “No” to ACTA – again
EU and U.S. Negotiators Block Broad Support of Low- and Middle-income Countries to Move Towards Binding Health and Development R&D Convention
EU Parliament Says No and No Again to EMA: Independent Groups Echo Decision
Health Activists and Consumers Ask for Greater Public Return on EU Health R&D Spending and a Turn to Needs-driven Innovation
Big Pharma Spends Over €40 Million per Year Lobbying in the EU, Dwarfing Public Health NGOs
Civil Society Calls on Members of the European Parliament to Condemn ACTA
Divide and Conquer: A look behind the scenes of the EU pharmaceutical industry lobby
Heading ACTA and Access to Medicines: Flawed Process, Rationale and Agreement
Protect Access to Medicines: Say “No” to ACTA
Business Conduct Guidelines
Complaints Procedure (EN)
Procedimiento de Querellas
Klachtenprocedure (Complaints Procedure – Dutch)
Unlocking the Mysteries of Access to Clinical Trials Data in the EU
Call to EU Leadership on Global Health Research & Development
2011
Statement on Medicines Patent Pool
Universal Access to Medicines for Non-Communicable Diseases
Drop in Pay-for-Delay Good for Access to Medicines in Europe
Resolution on Innovation and Access to Medical Technologies
Uso Racional: La influencia de la publicidad en el uso del medicamento
Statement on Conflicts of Interests delivered at WHA
Statement on EU India and EU Mercosur Free-Trade Negotiations
Medicines pay-for-delay back under the microscope
Transparency of European Medicines Regulation
2010